Base Year
Historical Year
Forecast Year
The acute lymphoblastic leukemia therapeutics market size was valued at USD 2.79 billion in 2023, driven by increasing demand of personalised treatment across the major markets. The market is expected to grow at a CAGR of 4.6% during the forecast period of 2024-2032, with the values likely to rise from USD 2.79 billion in 2024 to USD 4.19 billion by 2032.
Acute lymphoblastic leukemia (ALL) is a cancer of blood and bone marrow, specifically affecting the lymphocytes (white blood cells). It is the most common type of cancer in children but can also occur in adults. It accounts for 74% of the overall pediatric leukemia cases. The risk of developing the disease gradually declines until the mid-20s and begins to rise after a person attains the age of 50. ALL affects approximately 4 out of every 10 adults. While most cases affect children, the death rate is significantly higher in adults (about 4 out of 5).
Acute lymphoblastic leukemia therapeutics market demand is driven by the rising incidence of the disease in recent years. As per data released by the American Cancer Society in 2023, around 6,540 new ALL cases are expected to affect the United States population, out of which 3,660 cases are expected in males and 2,880 cases in females. The deaths associated with the disease are projected to be around 1,390 (700 in males and 690 in females). While it is not a common cancer, the average person’s lifetime risk of developing the disease is 1 in 1,000. The male community is more susceptible to this category of tumor than the females.
-therapeutics-market.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The acute lymphoblastic leukemia therapeutics market share is expected to be dominated by combination therapies, owing to their efficacy in reducing tumor progression and minimizing other side effects associated with the condition. In January 2023, the results of a clinical trial revealed that blinatumomab (Blincyto), when combined with chemotherapy, showed 83% improvement in the survival rate as opposed to those who were subjected to chemotherapy alone (65%).
With the rising popularity of targeted therapy to treat cancer, a class of tyrosine kinase inhibitors (TKI) has been found effective in treating newly diagnosed ALL in patients. One such example is Takeda Pharmaceutical’s Ponatinib , which is currently under phase I trial for pediatric Ph+ acute lymphoblastic leukemia. It prevents tumor progression by blocking BCR-ABL protein.
Asparaginase therapies are also considered as critical treatment alternative for acute lymphoblastic leukemia. Currently, the FDA has approved five asparaginase therapies. Owing to its reduced immunogenicity compared to native E. coli preparations and satisfactory pharmacokinetic profile, pegaspargase is used as the firsthand asparaginase therapeutic option. To meet the rising acute lymphoblastic leukemia therapeutics market demand, regulatory authorities around the world are approving new drug therapies for treatment.
In July 2023, the European Medicines Agency (EMA) showed a positive opinion on the authorization of marketing Jazz Pharmaceutical’s JZP458 (a recombinant Erwinia asparaginase or crisantaspase) in the region. L -asparaginase lowers the serum levels of L-asparagine, resulting in cell death. This is because the enzyme is present in the human body and not naturally synthesized by the leukemic cells. It is expected to be used as a constituent of a multi-agent chemotherapeutic routine for the treatment of acute lymphoblastic leukemia in adults as well as children who have developed silent inactivation or hypersensitivity to E. coli derived asparaginase.
Preventing recurrence of acute lymphoblastic leukemia is a key area of investigation amongst scientists. Hence, there is an emphasis on pairing standard leukemia treatments with new class of drugs to prevent relapse. In addition, immune checkpoint blockade that disrupts the pathway used by cancer cells to evade the immune system are also being evaluated in clinical trials. The search for new technologies and alternatives, coupled with improving technical advancements, is expected to support the acute lymphoblastic leukemia therapeutics market size in the forecast period.
-therapeutics-market-by-therapy-type.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Type
Market Breakup by Treatment
Market Breakup by Patient Type
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
-therapeutics-market-by-region.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The United States, with a well-established medical and research infrastructure is expected to lead the acute lymphoblastic leukemia therapeutics market share in upcoming years. The market size is further fueled by the inauguration of research centers with a vision to encourage research and innovation. In September 2023, Cincinnati Children's Hospital launched advanced leukemia therapies and research center that aims to integrate more research and clinical programs for improved patient outcomes.
In December 2023, Theseus Pharmaceuticals entered a merger agreement with Concentra Biosciences wherein the company will acquire Theseus Pharmaceuticals for a stock price of USD 3.90 and USD 4.05 in cash. The merger is focused on improving the lives of cancer patients with discovery, commercialization, and development of transformative targeted therapies.
In March 2023, Pfizer acquired Seagen for USD 43 billion to develop antibody drug candidates, a pioneer in the cancer class drugs. Such acquisitions are a clear indicator that the market for cancer therapeutics is anticipated to witness substantial growth in the forecast period.
The key features of the acute lymphoblastic leukemia therapeutics market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Patient Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 2.79 billion in 2023, driven by the increasing demand for personalised treatment across the major markets.
The market is anticipated to grow at a CAGR of 4.6% during the forecast period of 2024-2032, likely to reach a market value of USD 4.19 billion by 2032.
The market demand is driven by the increasing incidence of the disease in adults as well as children in recent years, along with surge in investments on research and development and rising partnerships amongst vital healthcare companies.
The major market trend revolves around using innovative alternatives such as immune checkpoint blockades and combining standard leukemia treatments with new class of drugs to prevent cancer recurrence.
Based on patient types, the market is divided into adults and paediatrics.
Based on disease type, the market is divided into B-cell acute lymphoblastic leukemia and C-cell acute lymphoblastic leukemia.
Chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy, among others are common technologies available in the market.
Major distribution channels include hospital pharmacy, retail pharmacy, and online pharmacy, among others.
The routes of administration can be oral and parenteral.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Novartis AG, F. Hoffmann-La Roche Ltd, Eisai Co Ltd., GlaxoSmithKline plc., Celegene Corporation, Bristol Myer Squibb Company, Pfizer Inc., Sanofi SA, Genmab A/S, Erytech Pharma, Takeda Pharmaceutical Company Limited, OBI Pharma, Astellas Pharma Inc., Medexus Pharma, Inc., and Kiadis Pharma.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share